Genetics and epigenetics of melanoma.

Genetics and epigenetics of melanoma. Oncol Lett. 2020 Nov;20(5):184 Authors: Zhang XY, Zhang PY Abstract [This retracts the article DOI: 10.3892/ol.2016.5093.]. PMID: 32934751 [PubMed - in process]
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research

Related Links:

This article summarizes the rationale for, and development of CDK inhibitors in melanoma, with their evolution from pan-CDK inhibitors to highly specific agents, throughout clinical trials and finally their potential future use. EXPERT OPINION: Whilst CDK inhibitors have been practice changing in breast cancer management, their efficacy is yet to be proven in melanoma. Combination with BRAF/MEK inhibitors has been hindered by dose-limiting toxicities, but their role may yet to be found within the spectrum of biomarker-derived personalized melanoma management. The effect that CDK inhibitors can have as an adjunct to imm...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Authors: Ribero S, Quaglino P, Sottile A, Fenu P, Sapino A PMID: 33034433 [PubMed - as supplied by publisher]
Source: Giornale Italiano di Dermatologia e Venereologia - Category: Dermatology Tags: G Ital Dermatol Venereol Source Type: research
In this study, we modeled an alternative strategy to amplify tumor antigen-specific TCR transgenic CD8+ T cells through limited application of a long-acting IL-2 fusion protein, mIL-2/mCD25, which selectively targets the high-affinity IL-2R. Here, mice were vaccinated with a tumor antigen and high-dose mIL-2/mCD25 was applied to coincide with the induction of the high affinity IL-2R on tumor-specific T cells. A single high dose of mIL-2/mCD25, but not an equivalent amount of IL-2, amplified the frequency and function of tumor-reactive CD8+ T effector (Teff) and memory cells. These mIL-2/mCD25-dependent effects relied on di...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
Condition:   Melanoma Interventions:   Biological: Nivolumab;   Biological: Pembrolizumab;   Radiation: Radiation Therapy;   Biological: Therapeutic Exchange Plasma Sponsors:   Mayo Clinic;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusions: The present meta-analysis revealed a potential link between periodontitis and esophageal cancer, prostate cancer, hematological malignancy, and melanoma of the skin. However, multi-center studies with large sample sizes and multivariable adjustments are still needed to support the conclusion. PMID: 33029095 [PubMed - in process]
Source: International Journal of Medical Sciences - Category: Biomedical Science Tags: Int J Med Sci Source Type: research
Publication date: Available online 8 October 2020Source: Redox BiologyAuthor(s): Liaisan R. Arslanbaeva, Massimo M. Santoro
Source: Redox Biology - Category: Biology Source Type: research
Condition:   Melanoma Interventions:   Biological: Nivolumab;   Biological: Pembrolizumab;   Radiation: Radiation Therapy;   Biological: Therapeutic Exchange Plasma Sponsors:   Mayo Clinic;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Title: DNA Analysis Might Reveal Melanoma RiskCategory: Health NewsCreated: 10/8/2020 12:00:00 AMLast Editorial Review: 10/9/2020 12:00:00 AM
Source: MedicineNet Cancer General - Category: Cancer & Oncology Source Type: news
Uveal melanoma (UM) is the commonest primary intraocular malignancy in adults. There is limited published data on lipid production in UM. Here, we describe the clinical, histological, immunohistochemical, and molecular findings in a ciliochoroidal melanoma with lipid production and expression of the enzyme HMG-CoA reductase. This case highlights an unusual UM tumour phenotype with a high-risk molecular metastatic profile and discusses tumour lipogenesis and activation of the mevalonate pathway as a potential therapeutic target in managing lipidised ciliochoroidal UM.Ocul Oncol Pathol
Source: Ocular Oncology and Pathology - Category: Opthalmology Source Type: research
Authors: Cammarata E, Giorgione R, Graziola F, Gironi LC, Zavattaro E, Savoia P PMID: 33026217 [PubMed - as supplied by publisher]
Source: Giornale Italiano di Dermatologia e Venereologia - Category: Dermatology Tags: G Ital Dermatol Venereol Source Type: research
More News: Cancer & Oncology | Genetics | Melanoma | Skin Cancer